Discover

News & Info

Trade

LongbridgeAI

Quote List Quote List

Maze Therapeutics(MAZE.US)

Event Tracking

Mar31

Mizuho analyst maintains buy rating on Maze Therapeutics, target price at $97

03:38

Mar28

LifeSci Capital and TD Cowen Initiate Buy Ratings on Maze Therapeutics

14:54

Mar26

Maze Therapeutics released FY2025 Q4 earnings on March 25 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6473 (forecast USD -0.7239)

03:00

Maze Therapeutics released FY2025 annual earnings on March 25 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.051 (forecast USD -3.123)

03:00

Feb4

Maze Therapeutics Executives Dispose of Company Common Stock

21:26

Jan16

Maze Therapeutics Updates Renal Disease Therapy R&D Pipeline

18:58

Schedules & Filings

Schedules

Filings

Mar25

Earning Release(EST)

FY2025 Q4 Earning Release (USD) Net Income -34.57 M, EPS -0.6473

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -30.09 M, EPS -0.66

Aug12

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -33.68 M, EPS -0.7699

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

Maze Therapeutics(MAZE.US)

Maze Therapeutics Stock Performance Chart